These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25678415)

  • 1. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder.
    Eswara JR; Heney NM; Wu CL; McDougal WS
    Urol Int; 2015; 94(4):401-5. PubMed ID: 25660255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection.
    Han B; Liang S; Jing Y; Cui D; An X; Zou Q; Wei H; Xia S
    Med Oncol; 2014 Apr; 31(4):912. PubMed ID: 24627238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
    Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
    Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
    Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Yabana T
    Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.